Kerendia (Finerenone)

Kerendia, a mineralocorticoid receptor antagonist, is used in conditions related to chronic kidney disease and diabetes.

• Chronic kidney disease associated with type 2 diabetes: slows progression of renal function decline and reduces albuminuria.
• Albuminuric diabetic kidney disease: decreases urinary albumin excretion, supporting kidney health.
• Cardiovascular risk in CKD with type 2 diabetes: may lower the incidence of major adverse cardiovascular events.

• Finerenone selectively blocks the mineralocorticoid receptor without steroidal activity. By antagonizing this receptor, it reduces aldosterone‑mediated signaling, which diminishes renal inflammation, oxidative stress, and fibrosis. The result is preservation of kidney structure and function in patients with diabetic kidney disease.

Finerenone may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Hyperkalaemia: elevated serum potassium levels.
• Dizziness or light‑headedness.
• Nausea or gastrointestinal discomfort.
• Headache.

Serious or Rare Side Effects

• Severe hyperkalaemia leading to cardiac arrhythmia.
• Acute kidney injury or worsening renal function.
• Significant hypotension.
• Allergic reactions such as rash or angioedema.
• Hepatic injury indicated by abnormal liver enzymes.

Finerenone requires careful monitoring and specific safety measures.

• Monitor serum potassium: check levels regularly to detect hyperkalaemia.
• Assess renal function: evaluate eGFR before initiation and during therapy.
• Adjust dose in severe renal impairment: consider reduced dosing or avoid use.
• Avoid concomitant potassium‑sparing agents: limit risk of excessive potassium.
• Use with caution in pregnancy: safety category unknown, weigh benefits against risks.
• Store at below 25°C: keep in the original pack, protect from moisture.

Finerenone can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid)

• Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalaemia.
• ACE inhibitors or ARBs: increase risk of elevated potassium and renal impairment.
• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): raise finerenone plasma concentrations.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug exposure.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can affect renal function.
• Thiazide diuretics: may alter electrolyte balance.
• Heparin: may potentiate hyperkalaemia.
• Other renin‑angiotensin system agents: require close laboratory monitoring.